search
Back to results

Pilot Efficacy Study of T2000 in Myoclonus Dystonia

Primary Purpose

Myoclonus

Status
Terminated
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
T2000
Sponsored by
Taro Pharmaceuticals USA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myoclonus focused on measuring Myoclonus Dystonia, Essential Myoclonus, Inherited Myoclonus, Dyskinesia, Movement Disorder

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients should meet diagnostic criteria for M-D based on the following criteria:

    • myoclonus is the primary feature; focal or segmental dystonia of any severity may also be present
    • symptoms began by age 20
    • a familial pattern should be present
    • neurological history should not be suggestive of a different neurological condition
    • investigations such as imaging, EEG and evoked potential tests should be normal
  • Patients will be eligible for this study if they are symptomatic on their current treatment, cannot tolerate current therapies, or are treatment naïve patients who have been explained treatment alternatives.

Exclusion Criteria:

  • Patients adequately controlled without side effects on a current M-D treatment
  • Current treatment with a barbiturate such as phenobarbital or primidone
  • Pregnant patients or patients who may become pregnant during the study
  • Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders
  • Patients with seizure disorders
  • Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin
  • Patient with significant general medical or clinical laboratory abnormalities

Sites / Locations

  • Investigator Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

T2000

Outcomes

Primary Outcome Measures

Effect of treatment on the movement disorder will be measured by a myoclonus scale and a dystonia scale as well as by assessment of overall functional status. Response at various dosages will be compared to baseline for all patients.

Secondary Outcome Measures

Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication.

Full Information

First Posted
July 20, 2007
Last Updated
December 19, 2013
Sponsor
Taro Pharmaceuticals USA
search

1. Study Identification

Unique Protocol Identification Number
NCT00506012
Brief Title
Pilot Efficacy Study of T2000 in Myoclonus Dystonia
Official Title
Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Myoclonus Dystonia: An Open Label Sequential Dose Escalation Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Terminated
Why Stopped
Slow Recruitment of eligible patients
Study Start Date
August 2007 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
October 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taro Pharmaceuticals USA

4. Oversight

5. Study Description

Brief Summary
This pilot study will evaluate the safety and efficacy of once daily T2000 when used to treat patients with Myoclonus Dystonia over a 12 week period.
Detailed Description
Myoclonus Dystonia (M-D) is a rare, inherited movement disorder in which patients experience myoclonus - sudden, brief, jerky involuntary motions, often in association with dystonia - involuntary sustained contractions causing twisting or abnormal posture. While most M-D patients respond significantly to alcohol, there are no approved medications for M-D. A variety of medications are currently used to treat M-D, but these treatments work in a small proportion of patients and provide only partial improvement in symptoms; their use is also limited by side-effects in many patients. T2000 is a medication currently under development for the treatment of movement disorders, including essential tremor (ET). Although T2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. In previous studies, T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET had major improvements in tremor. As would be expected for medications in this class, T2000 can cause sedation at high blood levels, such as may be seen when large doses are given to older individuals. In younger patients, T2000 caused only minimal side effects even when administered at high doses and for periods of several weeks to several months. The current study will evaluate the safety and efficacy of T2000 in patients with M-D. Patients will receive doses of T2000 beginning at 200 mg a day and increasing every other week by an additional 200 mg a day up to a maximal dose of 1000 mg a day. The total duration of treatment will be 12 weeks. Patient's symptoms of myoclonus and dystonia, as well as overall neurological examination, will be monitored throughout the study. The response to T2000 will be determined by comparing the severity of myoclonus and dystonia while patients are receiving T2000 compared to the symptoms observed without active medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myoclonus
Keywords
Myoclonus Dystonia, Essential Myoclonus, Inherited Myoclonus, Dyskinesia, Movement Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
T2000
Intervention Type
Drug
Intervention Name(s)
T2000
Intervention Description
T2000 at doses of 200 mg a day to 1000 mg a day
Primary Outcome Measure Information:
Title
Effect of treatment on the movement disorder will be measured by a myoclonus scale and a dystonia scale as well as by assessment of overall functional status. Response at various dosages will be compared to baseline for all patients.
Time Frame
Up to 12 weeks
Secondary Outcome Measure Information:
Title
Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication.
Time Frame
Up to 16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients should meet diagnostic criteria for M-D based on the following criteria: myoclonus is the primary feature; focal or segmental dystonia of any severity may also be present symptoms began by age 20 a familial pattern should be present neurological history should not be suggestive of a different neurological condition investigations such as imaging, EEG and evoked potential tests should be normal Patients will be eligible for this study if they are symptomatic on their current treatment, cannot tolerate current therapies, or are treatment naïve patients who have been explained treatment alternatives. Exclusion Criteria: Patients adequately controlled without side effects on a current M-D treatment Current treatment with a barbiturate such as phenobarbital or primidone Pregnant patients or patients who may become pregnant during the study Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders Patients with seizure disorders Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin Patient with significant general medical or clinical laboratory abnormalities
Facility Information:
Facility Name
Investigator Site
City
Toronto
State/Province
Ontario
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
17265458
Citation
Melmed C, Moros D, Rutman H. Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid). Mov Disord. 2007 Apr 15;22(5):723-7. doi: 10.1002/mds.21321.
Results Reference
background

Learn more about this trial

Pilot Efficacy Study of T2000 in Myoclonus Dystonia

We'll reach out to this number within 24 hrs